AINEWS
An EU funded consortium is testing a new class of targeted protein degrading drugs built from short synthetic DNA strands that recruit the cell's own recycling machinery, against a diabetic complication with no approved drug.
Diabetic foot ulcers kill roughly 1 in 20 patients within a year of onset and more than 4 in 10 within five. The standard treatment is a clean dressing. No approved drug addresses the runaway inflammation that keeps the wound from closing.
That gap is what an EU-funded research consortium called APTADEGRAD, led by Spanish biotech Lincbiotech, is trying to fill. The project runs through the end of 2027. It is the named attempt to build a disease-modifying therapy for diabetic foot ulcers (DFUs), a complication that affects roughly a quarter of people with diabetes at some point in their lives.
More than 800 million people live with diabetes worldwide. Germany performs an estimated 34,500 diabetes-related amputations a year. The UK National Health Service spends the equivalent of about EUR 1.1 billion (roughly USD 1.2 billion at recent rates) annually on DFUs and amputations. Those figures come from the APTADEGRAD project dossier, not independent peer-reviewed epidemiology. They are best read as project-supplied context, not authoritative prevalence.
The mechanism APTADEGRAD is testing borrows from a corner of cell biology most readers have never heard of. Inside every cell, a recycling system called autophagy breaks down damaged proteins and other waste. In a chronic wound, that system stalls, inflammation runs unchecked, and the skin cannot close. The project is using aptamer-based LYTACs (short synthetic DNA strands tethered to a targeting molecule) to flag the inflammatory proteins for destruction by the cell's own lysosomes, the organelles that do the actual waste disposal.
It is a research-stage hypothesis, not a therapy. CORDIS, the EU's research project database, lists APTADEGRAD under project ID 101099063 with the title "A novel aptamer-based LYTACs for diabetic wounds." Adjacent peer-reviewed work, a 2024 PLOS ONE study on autophagy and oxidative stress in DFU healing, supports the broader mechanistic lane the project sits in. The consortium has not yet published clinical efficacy data, and the project leader is also the CEO of one of the commercial partners.
Lincbiotech's CEO, Juan Ruiz-Constantino, has framed the work as a bet on a treatment class that can address the disease mechanism rather than the symptom, according to the Horizon Magazine feature on the project. Independent validation matters: a peer-reviewed LYTAC-DFU paper, a successful animal-model readout, or a first human trial would be the next signal worth watching.
The treatment gap is the story. Until a drug is approved that directly addresses the disease mechanisms driving diabetic foot ulcers, the amputation count and the mortality curve are unlikely to bend. Today's standard of care is wound management, not disease management. Clinicians clean, debride, and dress the lesion, then wait, sometimes for months, for the body to close it on its own. A disease-modifying therapy would change that workflow, shortening the open-wound window and, in theory, cutting the path from ulcer to amputation.
The CORDIS project record, the APTADEGRAD project site, the consortium's planned publications, and the 2027 project endpoint are the calendar a reader can monitor in the meantime.